Abstract This study assessed the relationship between meticillin-resistant Staphylococcus aureus (MRSA) prevalence in 26 European countries with two key socioeconomic parameters, namely, gross domestic product per capita (GDP) and infant mortality rate (IMR). Whilst no significant relationship was identified between MRSA and GDP (Spearman correlation: −0.387; 95% confidence interval [CI]: −0.674 to 0.000; p=0.0528), a significant correlation was evident between MRSA and IMR (Spearman correlation: 0.545; 95% CI: 0.208 to 0.766; p=0.005).
Abstract This study assessed the relationship between meticillin-resistant Staphylococcus aureus (MRSA) prevalence in 26 European countries with two key socioeconomic parameters, namely, gross domestic product per capita (GDP) and infant mortality rate (IMR). Whilst no significant relationship was identified between MRSA and GDP (Spearman correlation: −0.387; 95% confidence interval [CI] : −0.674 to 0.000; p=0.0528), a significant correlation was evident between MRSA and IMR (Spearman correlation: 0.545; 95% CI: 0.208 to 0.766; p=0.005). The elimination of a widely outlying data point retained significance. Various studies have shown IMR to be a good marker of healthcare expenditure and it is, therefore, reasonable to postulate that one possible factor in the multi-factorial epidemiology of MRSA in Europe is the level and effectiveness of healthcare expenditure within the individual countries.
Over recent years, public awareness and interest in meticillin-resistant Staphylococcus aureus (MRSA) has increased significantly. One reason for this has been the greater availability of surveillance data at the pan-European level through good quality comparable data from the successful European Antimicrobial Resistance Surveillance System (EARSS, http://www.rivm.nl/earss) [1] . This preliminary study attempted to determine relationships between MRSA prevalence at the country level and two key socioeconomic parameters: gross domestic product per capita (GDP) and infant mortality rate (IMR). The GDP of a country is defined as the market value of all final goods and services produced within that nation in a given period of time. It is used by economists as a way of measuring the size of a country's economic strength and purchasing power. IMR refers to the number of newborns dying within their first 12 months of life, divided by the number of live births during that year. IMR has been used as a useful indicator of a country's level of health development; in fact, public spending on health and better access to healthcare facilities are critical determinants of IMR [2, 3] .
Data was obtained from publically available documents. MRSA figures for the year 2005 were sourced from the EARSS annual report 2005 (National Institute for Public Health and the Environment, Bilthoven, The Netherlands). This reported, among other things, the proportion of S. aureus, isolated from routine blood cultures, that were identified as meticillin-resistant by the participating laboratories within the EARSS project during the year 2005. In turn, MRSA proportions have been shown to be strongly correlated to incidence [4] . GDP MRSA proportions from the 27 countries varied from 0.01 to 71.7% (mean: 23.41%), whilst GDP for the same countries ranged from $8,200 to $55,600 (mean: $26,351). Although the more affluent nations in Europe appeared to be the ones with better MRSA control, a substantial degree of heterogeneity was evident. Several countries with relatively high GDP still had MRSA proportions that were much higher than those for less affluent nations. Rank correlation between MRSA proportions for the different European countries and the GDP per capita for that same country yielded a Spearman correlation index (rho) of −0.387 (95% confidence interval [CI]: −0.674 to 0.000) and a p-value of 0.0528.
On the other hand, when the same MRSA proportions were plotted against IMR, the goodness of fit was much more evident, with a substantial proportion of the points falling close to the line of best fit (Fig. 1) . This was confirmed by a Spearman correlation index (rho) of 0.545 (95% CI for rho = 0.208 to 0.766) and p=0.005. In order to ensure that the widely outlying data point was not unduly influencing the correlation, the analysis was repeated by eliminating this data set from the analysis. Nevertheless, a statistically significant result was still obtained, albeit slightly inferior to that of the complete range; the Spearman's coefficient of rank correlation (rho) was 0.491 (95% CI for rho = 0.127 to 0.738) and it had a p-value of 0.014.
The lack of a significant relationship between the levels of GDP and MRSA proportions in the individual countries suggests that economic strength and purchasing power does not automatically result in improved prevention of healthcare-associated infections such as MRSA. This is not surprising, since the mere economic affluence of a nation would not necessarily translate into better healthcare outcomes, unless that same economic affluence is channelled appropriately into effective expenditure and use. It is in this context that the strong relationship between IMR rates and MRSA proportions in European countries is very interesting. Indeed, Elola et al. found that infant mortality was a better predictor of healthcare expenditure than GDP [5] . Various elements of healthcare expenditure and quality have been linked to IMR by other authors. Babazono and Hillman suggested that perinatal and infant mortality was related to the number of hospital beds [2] , whilst the number of physicians per capita was found to be a significant variable for infant mortality in 12 countries within the Organisation for Economic Co-operation and Development (OECD) [6] . Furthermore, Wolfe and Gabay showed that increased medical expenditure led to improvements in several health outcomes, including IMR [7] . This would be more relevant in a region or continent, such as Europe, where public health has made substantial progress over the past century. To a reasonable degree, these countries exhibit no cataclysmic shifts in general living conditions between each other, as evident from the GDP per capita of all of the studied countries, which was within 2 standard deviations of the median. In such a background, a major input to reducing infant mortality would, therefore, be the ability to increase survival in low birth weight infants, where improved neonatal and obstetric services are important contributors [8] .
Just as it seems to be a determinant for IMR, the degree of investment in healthcare systems would almost certainly play a critical role in determining the success or otherwise of MRSA control in the different European countries. Whilst direct references to the role of healthcare expenditure for improved MRSA control at a pan-national level have not been highlighted in the medical literature, both capital and manpower investment within hospitals are critical in order to obtain effective MRSA control [9] .
Despite the rationality of this argumentation, it would be unacceptably simplistic to assume that the only determinant for successful MRSA control is just the level and effectiveness of funds pumped into the country's healthcare system. This is evident from the correlation coefficient of 0.545. In addition, both sets of statistics are recognised to possess inherent sources of error. There is considerable debate on the different practices and cut-offs to define infant mortality in different countries, which, of course, have implications on the rate itself [10] . The MRSA proportions reported by EARSS are based on diverse population coverage in each of the participating European countries. Potential bias may be present if the proportion of the population under study is either low or partial. Furthermore, the model may not be applicable in other continents outside of Europe, especially if the GDP varies substantially from the European median.
Nevertheless, despite these limitations, the identified correlation between MRSA and IMR cannot be easily ignored and would justify a more extensive study into healthcare expenditure and utilisation, and its impact on MRSA and other healthcare-associated infections. 
